SPX3,785.38-33.45 -0.88%
DIA307.82-2.23 -0.72%
IXIC11,028.74-149.16 -1.33%

BRIEF-Sonnet Biotherapeutics Announces Results From Preclinical Combination Study Of SON-1010 With Anti-PD1 Checkpoint Inhibition

reuters.com · 06/09/2022 07:35
BRIEF-Sonnet Biotherapeutics Announces Results From Preclinical Combination Study Of SON-1010 With Anti-PD1 Checkpoint Inhibition

- Sonnet Biotherapeutics Holdings Inc SONN:

  • SONNET BIOTHERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM A PRECLINICAL COMBINATION STUDY OF SON-1010 WITH ANTI-PD1 CHECKPOINT INHIBITION

  • SONNET - TUMOR VOLUME GROWTH INHIBITION IMPROVEMENTS OBSERVED WITH THE COMBINATION OF SON-1010 AND A COMMERCIALLY AVAILABLE ANTI-PD1 ANTIBODY

  • SONNET - COMBINATION OF SON-1010 WITH ANTI-PD1 INCREASED SURVIVAL RATE

Source text for Eikon: ID:nACSZXnW0a

Further company coverage: SONN


((Reuters.Briefs@thomsonreuters.com;))